BF
Therapeutic Areas
Tosk Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TK-90 | Prevention of chemotherapy/radiation-induced mucositis | Proof of Concept |
| TK-39 | Prevention of anthracycline/Herceptin-induced cardiotoxicity | Preclinical |
| TK-KRAS | Targeting mutant KRAS-driven cancers (e.g., pancreatic, colorectal, lung) | Discovery/Optimization |
| TK-88 | Prevention of kidney toxicity, neuropathy, and hearing loss from platinum-based chemotherapies | Preclinical |